Publications

Selected Recent Publications

• Herold KC, Hagopian W, Auger J, Poumain-Ruiz E, Taylor L, Donaldson D,
• Gitelman S, Harlan D, Xu D, Zivin R, and Bluestone JA. Anti-CD3 mAb
  (hOKT3ƒ×1(Ala-Ala)) in patients with new onset Type 1 diabetes mellitus.  New
  Eng J Med 2002; 346: 1692-8.
• Herold KC, Burton JB, Francois, F, Poumain-Ruiz E, Glandt M, and Bluestone
  JA. Activation of human T cells by FcR non-binding anti-CD3 mAb,
  hOKT3ƒ×1(Ala-Ala). J Clin Invest 2003; 11:409-418.
• Bisikirska B, Colgan J, Luban J, Bluestone JA, and Herold KC. Human T cell
  receptor signaling with modified anti-CD3 monoclonal antibody expands CD8+ T
  cells and induces regulatory CD8+CD25+ cells J. Clin Invest 115: 2005;
  2904-2913.
• Herold KC, Bisikirska B, Gitelman SE, Masharani U, Hagopian W, Donaldson D,
  Rother K, Diamond B, Harlan DM, and Bluestone JA. A single course of anti-CD3
  mAb OKT3£^1(Ala-Ala) results in improvement in insulin secretion and clinical
  parameters for at least 2 years after onset of Type 1 diabetes Diabetes 2005;
  54:1763-9.
• Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, and
  vonHerrath.  A novel combinatorial therapy in recent-onset autoimmune diabetes:
  Synergy of anti-CD3 and nasal proinsulin to induce regulatory T cells J. Clin
  Invest 2006; 116: 1371-1381.
• Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B,
  Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA,
  Herold KC.Analysis of T-cell assays to measure autoimmune responses in subjects
  with type 1 diabetes: results of a blinded controlled study.
  Diabetes. 2006 Sep;55(9):2588-94.
• Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC.
  Effects of Autoimmunity and Immune Therapy on {beta}-Cell Turnover in Type 1
  Diabetes. Diabetes. 2006;55(12):3238-45.